Jj. Berman et al., IDEAS IN PATHOLOGY - PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE-CANCER - NO REDUCTION IN GLEASON SCORES, Modern pathology, 7(4), 1994, pp. 487-489
Skepticism regarding prostate-specific antigen (PSA) screening arises
from the possibility that screening procedures increase the yield of d
iagnosed prostate cancers occurring in an indolent form that does not
require treatment. If PSA screening serves only to increase the yield
of clinically trivial prostate cancer, one would expect a drop in the
average Gleason score of prostate cancers detected with PSA screening
compared with prostate cancers detected before the advent of PSA scree
ning. In a 3-yr study of newly diagnosed prostate cancer, there was al
most a 7-fold increase in PSA screening tests ordered between 1989 and
1992 and a greater than 2-fold increase in the number of newly diagno
sed prostate cancers. In the same time period, the average Gleason sco
res of newly diagnosed prostate cancer increased slightly (from 6.2 to
6.5). In this study there was no prognostic difference (as predicted
by Gleason score) between prostate cancers in populations whose cancer
s were diagnosed before and after the increased use of PSA as a screen
ing tool.